Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...2627282930313233343536...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Antiangiogenic therapy of neovascular age-related macular degeneration (Pubmed Central) -  Feb 28, 2021   
    Even though the topic of nAMD therapy is widely highlighted in modern ophthalmology, today there are many aspects that require targeted solutions. The main controversial issues that determine the complexity of therapy and patient management include discrepancies in determination of reference points (disease activity criteria) for implementation of anti-VEGF dosing regimens, patients' compliance, prioritization issues in treatment, its continuity with potential for the increase of intervals between injections and monitoring visits.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity. (Pubmed Central) -  Feb 27, 2021   
    The main controversial issues that determine the complexity of therapy and patient management include discrepancies in determination of reference points (disease activity criteria) for implementation of anti-VEGF dosing regimens, patients' compliance, prioritization issues in treatment, its continuity with potential for the increase of intervals between injections and monitoring visits. The IVR might contribute to microvascular changes in the macular zone, such as reducing the central foveal VLD and PD, while the LP might contribute to microstructural changes, such as smaller FAZ and thicker CFT.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Ranibizumab: A Review in Retinopathy of Prematurity. (Pubmed Central) -  Feb 27, 2021   
    Overall, ranibizumab is an effective and generally well tolerated treatment for ROP and is not associated with systemic VEGF suppression. Although results for its long-term effects on vision are not yet available, ranibizumab is a promising alternative option to laser therapy for treating ROP.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Stopper Position and Volume Injected in Prefilled Syringes () -  Feb 23, 2021 - Abstract #WEC2021WEC_24;    
    The stopper was positioned at specific distances behind the preprinted mark in ranibizumab and aflibercept PFS... Small changes in stopper position have significant impacts on volume and dose injected
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Rayoqta (abicipar pegol) / Molecular Partners, AbbVie
    Journal:  Abicipar pegol for neovascular age-related macular degeneration. (Pubmed Central) -  Feb 23, 2021   
    Modifications to reduce pro-inflammatory components resulted in reduced inflammation (9.8%) in the MAPLE study. If this high inflammation rate can be further reduced, abicipar has the potential to decrease treatment burden for nAMD patients.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Age-related macular degeneration: a review of current therapies and new treatments. (Pubmed Central) -  Feb 16, 2021   
    Current studies are focused on new anti-vascular endothelial growth factor drugs, nucleoside reverse transcriptase inhibitors, antibody against sphingosine-1-phosphate, anti-platelet-derived growth factor, gene therapy, and RNA interference. The results of ongoing clinical studies may improve the therapy of age-related macular degeneration.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal, HEOR, Real-World Evidence:  Real-World Treatment Patterns and Vision Outcomes with Ranibizumab for Diabetic Macular Edema. (Pubmed Central) -  Feb 13, 2021   
    Intravitreal ranibizumab for diabetic macular edema was effective in a real-world clinical setting, with most eyes gaining or maintaining vision. Compared with randomized prospective clinical trials, patients received less frequent injections and achieved lower vision gains.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up. (Pubmed Central) -  Feb 9, 2021   
    The abnormal arterial constriction and the abolished increase in AVD seen only in eyes with DME indicate an impairment of vascular autoregulation and oxygen distribution and a reduced neuroretinal metabolism in the diabetic retina with a significant impact on inner retinal oxygen consumption shortly after IVI. Our study demonstrates that ranibizumab and aflibercept in a PRN regimen lead to a significant increase of BCVA and decrease in central foveal thickness in treatment-naive patients with myopic CNV after 24 months.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography. (Pubmed Central) -  Feb 7, 2021   
    During ranibizumab therapy, external limiting membrane visibility showed a higher sensitivity (100%) compared with fuzzy borders and subretinal hyperreflective exudation (66.6%) while displaying an equal specificity of 100%...The study confirms that the new indicators of myopic choroidal neovascularization activity are more reliable than the presence or absence of retinal fluid. Optical coherence tomography angiography identified myopic choroidal neovascularization in most patients in the diagnostic phase and during treatment monitoring and could be considered as an alternative to fluorescein angiography in selected patients.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema. (Pubmed Central) -  Feb 7, 2021   
    However, there were no significant changes of the other five factors/cytokines (placental growth factor, soluble intercellular adhesion molecule-1, interleukin-6, interleukin-12, and interleukin-13) at recurrence after intravitreal ranibizumab injection compared with baseline. These findings suggest that persistent inflammation may influence the recurrence of macular edema in branch retinal vein occlusion patients, and that adding steroid therapy might be an effective strategy for preventing recurrence.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity. (Pubmed Central) -  Feb 7, 2021   
    Aggressive posterior retinopathy of prematurity is a serious, rapidly progressing form of retinopathy of prematurity that requires quick and proper management. This study indicates that primary treatment with ranibizumab and laser photocoagulation on recurrence provide favorable anatomical outcomes.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Emerging drugs for the treatment of diabetic retinopathy. (Pubmed Central) -  Feb 4, 2021   
    Faricimab, active on Tie-2 receptors, is being evaluated in two phase 3 clinical trials. Further knowledge on the efficacy and safety of these drugs is necessary before their final approval for the treatment of diabetic retinopathy.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Choroidal osteoma: the varied response of subretinal fluid to anti-VEGF agents. (Pubmed Central) -  Feb 2, 2021   
    Furthermore, integrated analyses by an in vivo rabbit model and in vitro assay system using THP-1 cells would be useful to evaluate the immunological risk of HCPs. The present case shows a remarkable long-term response of the choroidal neovascular membrane and serous retinal detachment associated with choroidal osteoma to two injections of ranibizumab which is an anti-vascular endothelial growth factor (anti-VEGF) agent.